Dr. Allen Reitz received his Ph.D. in Chemistry from the University of California, San Diego, working with Prof. Murray Goodman. He has had more than 37 years of experience in the pharmaceutical industry, including nearly 26 years with Johnson & Johnson. He has ~160 primary peer reviewed scientific publications, 66 issued U.S. patents, 20 book contributions, and 12 literature reviews. He is Editor of Current Topics in Medicinal Chemistry and on the Editorial Advisory Board of ACS Med Chem. Lett., and is co-inventor of eight drug candidates that have entered clinical trials including mazapertine and troriluzole, the latter of which is currently in four Phase II/III clinical trials.
He has extensive experience in project and portfolio management, target validation, hit triage, hit to lead and lead optimization medicinal chemistry, eADME profiling, and preclinical candidate selection. He is also Adjunct Professor at Drexel University College of Medicine and holds an Executive Masters in Technology Management from the University of Pennsylvania (Penn Engineering & The Wharton School).
Dr. Reitz founded Fox Chase Chemical Diversity Center, Inc. (FCCDC) in 2008. FCCDC is an early stage biomedical research company with laboratories in King of Prussia and Doylestown, PA. Dr. Reitz is also a founder and CEO of ALS Biopharma, LLC, focusing on amyotrophic lateral sclerosis, and co-founder and President of the non-profit Pennsylvania Drug Discovery Institute (PDDI).